サマリー

The global pharmacovigilance market grew at a CAGR of around 10% during 2015-2020. Pharmacovigilance (PV) is the pharmacological science concerning the detection, assessment, understanding and prevention of unfavorable effects with pharmaceutical products. It plays a pivotal role in identifying previously unknown adverse effects, recognizing changes in the frequency or severity, and assessing the risks and benefits of drugs to determine required actions. It also ensures the accuracy of communicated information to healthcare professionals and patients. At present, PV is widely used to understand the effects of drugs on individuals worldwide.

The increasing prevalence of lifestyle diseases, such as hypertension, diabetes, and cardiac disorders, has resulted in the rising consumption of drugs worldwide. This, in confluence with the growing incidences of adverse drug reactions (ADRs), represents one of the key factors driving the global pharmacovigilance market. Besides this, the key players are introducing advanced platforms to ensure automated ADR reporting, which is contributing to the market growth. They are also focusing on improving the manufacturing operations and streamlining research and development (R&D) on account of a competitive environment. Furthermore, leading pharmaceutical companies are undertaking numerous initiatives to conduct clinical trials and generate awareness about the proper utilization of medicines. This, in turn, is facilitating the growth of the pharmacovigilance market. Additionally, the coronavirus disease (COVID-19) outbreak has resulted in the urgent need for a vaccine, which has created numerous opportunities for the market players. Apart from this, pharmaceutical manufacturers are shifting towards outsourcing pharmacovigilance operations to third parties on account of the associated benefits, such as increasing internal resource flexibility and better outcomes over shorter periods. Looking forward, IMARC Group expects the global pharmacovigilance market to exhibit strong growth during the next five years.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global pharmacovigilance market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, service provider, product life cycle, type, process flow, therapeutic area and end use.

Breakup by Service Provider:

In-house
Contract Outsourcing

Breakup by Product Life Cycle:

Pre-clinical
Phase I
Phase II
Phase III
Phase IV

Breakup by Type:

Spontaneous Reporting
Intensified ADR Reporting
Targeted Spontaneous Reporting
Cohort Event Monitoring
EHR Mining

Breakup by Process Flow:

Case Data Management
Case Logging
Case Data Analysis
Medical Reviewing and Reporting
Signal Detection
Adverse Event Logging
Adverse Event Analysis
Adverse Event Review and Reporting
Risk Management System
Risk Evaluation System
Risk Mitigation System

Breakup by Therapeutic Area:

Oncology
Neurology
Cardiology
Respiratory Systems
Others

Breakup by End Use:

Pharmaceuticals Companies
Biotechnology Companies
Medical Device Companies
Others

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Accenture plc, ArisGlobal LLC, BioClinica Inc. (Cinven Partners LLP), Capgemini, Cognizant, International Business Machines Corporation, ICON plc., IQVIA Inc., ITClinical, Parexel International Corporation and Wipro Limited.

Key Questions Answered in This Report:
How has the global pharmacovigilance market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global pharmacovigilance market?
What are the key regional markets?
What is the breakup of the market based on the service provider?
What is the breakup of the market based on the product life cycle?
What is the breakup of the market based on the type?
What is the breakup of the market based on the process flow?
What is the breakup of the market based on the therapeutic area?
What is the breakup of the market based on the end use?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global pharmacovigilance market and who are the key players?
What is the degree of competition in the industry?

ページTOPに戻る

目次

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Pharmacovigilance Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Service Provider
6.1 In-house
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Contract Outsourcing
6.2.1 Market Trends
6.2.2 Market Forecast
7 Market Breakup by Product Life Cycle
7.1 Pre-clinical
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Phase I
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Phase II
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Phase III
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Phase IV
7.5.1 Market Trends
7.5.2 Market Forecast
8 Market Breakup by Type
8.1 Spontaneous Reporting
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Intensified ADR Reporting
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Targeted Spontaneous Reporting
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Cohort Event Monitoring
8.4.1 Market Trends
8.4.2 Market Forecast
8.5 EHR Mining
8.5.1 Market Trends
8.5.2 Market Forecast
9 Market Breakup by Process Flow
9.1 Case Data Management
9.1.1 Market Trends
9.1.2 Major Types
9.1.2.1 Case Logging
9.1.2.2 Case Data Analysis
9.1.2.3 Medical Reviewing and Reporting
9.1.3 Market Forecast
9.2 Signal Detection
9.2.1 Market Trends
9.2.2 Major Types
9.2.2.1 Adverse Event Logging
9.2.2.2 Adverse Event Analysis
9.2.2.3 Adverse Event Review and Reporting
9.2.3 Market Forecast
9.3 Risk Management System
9.3.1 Market Trends
9.3.2 Major Types
9.3.2.1 Risk Evaluation System
9.3.2.2 Risk Mitigation System
9.3.3 Market Forecast
10 Market Breakup by Therapeutic Area
10.1 Oncology
10.1.1 Market Trends
10.1.2 Market Forecast
10.2 Neurology
10.2.1 Market Trends
10.2.2 Market Forecast
10.3 Cardiology
10.3.1 Market Trends
10.3.2 Market Forecast
10.4 Respiratory Systems
10.4.1 Market Trends
10.4.2 Market Forecast
10.5 Others
10.5.1 Market Trends
10.5.2 Market Forecast
11 Market Breakup by End Use
11.1 Pharmaceuticals Companies
11.1.1 Market Trends
11.1.2 Market Forecast
11.2 Biotechnology Companies
11.2.1 Market Trends
11.2.2 Market Forecast
11.3 Medical Device Companies
11.3.1 Market Trends
11.3.2 Market Forecast
11.4 Others
11.4.1 Market Trends
11.4.2 Market Forecast
12 Market Breakup by Region
12.1 North America
12.1.1 United States
12.1.1.1 Market Trends
12.1.1.2 Market Forecast
12.1.2 Canada
12.1.2.1 Market Trends
12.1.2.2 Market Forecast
12.2 Asia-Pacific
12.2.1 China
12.2.1.1 Market Trends
12.2.1.2 Market Forecast
12.2.2 Japan
12.2.2.1 Market Trends
12.2.2.2 Market Forecast
12.2.3 India
12.2.3.1 Market Trends
12.2.3.2 Market Forecast
12.2.4 South Korea
12.2.4.1 Market Trends
12.2.4.2 Market Forecast
12.2.5 Australia
12.2.5.1 Market Trends
12.2.5.2 Market Forecast
12.2.6 Indonesia
12.2.6.1 Market Trends
12.2.6.2 Market Forecast
12.2.7 Others
12.2.7.1 Market Trends
12.2.7.2 Market Forecast
12.3 Europe
12.3.1 Germany
12.3.1.1 Market Trends
12.3.1.2 Market Forecast
12.3.2 France
12.3.2.1 Market Trends
12.3.2.2 Market Forecast
12.3.3 United Kingdom
12.3.3.1 Market Trends
12.3.3.2 Market Forecast
12.3.4 Italy
12.3.4.1 Market Trends
12.3.4.2 Market Forecast
12.3.5 Spain
12.3.5.1 Market Trends
12.3.5.2 Market Forecast
12.3.6 Russia
12.3.6.1 Market Trends
12.3.6.2 Market Forecast
12.3.7 Others
12.3.7.1 Market Trends
12.3.7.2 Market Forecast
12.4 Latin America
12.4.1 Brazil
12.4.1.1 Market Trends
12.4.1.2 Market Forecast
12.4.2 Mexico
12.4.2.1 Market Trends
12.4.2.2 Market Forecast
12.4.3 Others
12.4.3.1 Market Trends
12.4.3.2 Market Forecast
12.5 Middle East and Africa
12.5.1 Market Trends
12.5.2 Market Breakup by Country
12.5.3 Market Forecast
13 SWOT Analysis
13.1 Overview
13.2 Strengths
13.3 Weaknesses
13.4 Opportunities
13.5 Threats
14 Value Chain Analysis
15 Porters Five Forces Analysis
15.1 Overview
15.2 Bargaining Power of Buyers
15.3 Bargaining Power of Suppliers
15.4 Degree of Competition
15.5 Threat of New Entrants
15.6 Threat of Substitutes
16 Price Analysis
17 Competitive Landscape
17.1 Market Structure
17.2 Key Players
17.3 Profiles of Key Players
17.3.1 Accenture plc
17.3.1.1 Company Overview
17.3.1.2 Product Portfolio
17.3.1.3 Financials
17.3.1.4 SWOT Analysis
17.3.2 ArisGlobal LLC
17.3.2.1 Company Overview
17.3.2.2 Product Portfolio
17.3.3 BioClinica Inc. (Cinven Partners LLP)
17.3.3.1 Company Overview
17.3.3.2 Product Portfolio
17.3.3.3 SWOT Analysis
17.3.4 Capgemini
17.3.4.1 Company Overview
17.3.4.2 Product Portfolio
17.3.5 Cognizant
17.3.5.1 Company Overview
17.3.5.2 Product Portfolio
17.3.5.3 Financials
17.3.5.4 SWOT Analysis
17.3.6 International Business Machines Corporation
17.3.6.1 Company Overview
17.3.6.2 Product Portfolio
17.3.6.3 Financials
17.3.6.4 SWOT Analysis
17.3.7 ICON plc.
17.3.7.1 Company Overview
17.3.7.2 Product Portfolio
17.3.7.3 Financials
17.3.7.4 SWOT Analysis
17.3.8 IQVIA Inc.
17.3.8.1 Company Overview
17.3.8.2 Product Portfolio
17.3.8.3 Financials
17.3.8.4 SWOT Analysis
17.3.9 ITClinical
17.3.9.1 Company Overview
17.3.9.2 Product Portfolio
17.3.10 Parexel International Corporation
17.3.10.1 Company Overview
17.3.10.2 Product Portfolio
17.3.10.3 SWOT Analysis
17.3.11 Wipro Limited
17.3.11.1 Company Overview
17.3.11.2 Product Portfolio
17.3.11.3 Financials
17.3.11.4 SWOT Analysis